Table 1

Participant characteristics

CON-A (n = 8)T1D-A (n = 8)CON-I (n = 10)T1D-I (n = 10)
Anthropometric and demographic data
Male/female sex7/17/16/46/4
 Age (years)29.6 ± 4.530.1 ± 6.825.8 ± 5.926.1 ± 7.8
 BMI (kg · m−2)23.5 ± 2.422.7 ± 3.423.8 ± 1.923.2 ± 1.9
 Fat mass (%)16.8 ± 3.718.2 ± 5.919.6 ± 5.419.9 ± 7.5
 Smoking status
  Smoker1122
  Nonsmoker7788
 HbA1c (%)5.3 ± 0.26.8 ± 0.7‡‡‡**5.3 ± 0.39.0 ± 0.7***
 HbA1c (mmol/mol)34 ± 2.251 ± 7.7‡‡‡**34 ± 3.375 ± 7.7***
 Diabetes duration (years)4.3 ± 3.5‡‡‡10.7 ± 3.7
 Age at disease diagnosis24.8 ± 8.115.4 ± 9.4
 Insulin delivery (MDI/CSII)4/44/6
 Insulin dose (units · kg−1 · day−1)0.48 ± 0.14‡‡‡0.78 ± 0.12
Accelerometry (min · day−1)
 Light + moderate + vigorous87.1 ± 26.572.9 ± 23.170.1 ± 18.976.5 ± 19.6
  • Data are mean ± SD or n. Fat mass was measured by DXA; HbA1c recorded just before exercise. CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections.

  • Significantly different from their respective CON group (Wilcoxon test):

  • **P < 0.01,

  • ***P < 0.001.

  • Significantly different from T1D-I:

  • P < 0.05,

  • ‡‡‡P < 0.001.